India · Delayed Price · Currency is INR Kabra Drugs Statistics
Total Valuation
Kabra Drugs has a market cap or net worth of INR 441.91 million. The enterprise value is 233.30 million.
| Market Cap | 441.91M |
| Enterprise Value | 233.30M |
Important Dates
The next estimated earnings date is Thursday, November 13, 2025.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Kabra Drugs has 23.71 million shares outstanding. The number of shares has increased by 260.13% in one year.
| Current Share Class | 23.71M |
| Shares Outstanding | 23.71M |
| Shares Change (YoY) | +260.13% |
| Shares Change (QoQ) | +26.98% |
| Owned by Insiders (%) | 20.66% |
| Owned by Institutions (%) | 0.24% |
| Float | 18.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.17 |
| PB Ratio | 1.79 |
| P/TBV Ratio | 1.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -22.44 |
| EV / Sales | 3.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -7.53% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 2.31M |
| Profits Per Employee | -335,387 |
| Employee Count | 31 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Kabra Drugs has paid 5,000 in taxes.
| Income Tax | 5,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +74.73% in the last 52 weeks. The beta is -0.04, so Kabra Drugs's price volatility has been lower than the market average.
| Beta (5Y) | -0.04 |
| 52-Week Price Change | +74.73% |
| 50-Day Moving Average | 18.96 |
| 200-Day Moving Average | 11.52 |
| Relative Strength Index (RSI) | 53.77 |
| Average Volume (20 Days) | 61,665 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kabra Drugs had revenue of INR 71.66 million and -10.40 million in losses. Loss per share was -0.66.
| Revenue | 71.66M |
| Gross Profit | 4.16M |
| Operating Income | -16.80M |
| Pretax Income | -10.39M |
| Net Income | -10.40M |
| EBITDA | n/a |
| EBIT | -16.80M |
| Loss Per Share | -0.66 |
Balance Sheet
The company has 212.99 million in cash and 4.37 million in debt, giving a net cash position of 208.62 million or 8.80 per share.
| Cash & Cash Equivalents | 212.99M |
| Total Debt | 4.37M |
| Net Cash | 208.62M |
| Net Cash Per Share | 8.80 |
| Equity (Book Value) | 246.55M |
| Book Value Per Share | 13.15 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 5.81%, with operating and profit margins of -23.44% and -14.51%.
| Gross Margin | 5.81% |
| Operating Margin | -23.44% |
| Pretax Margin | -14.50% |
| Profit Margin | -14.51% |
| EBITDA Margin | n/a |
| EBIT Margin | -23.44% |
| FCF Margin | n/a |
Dividends & Yields
Kabra Drugs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -260.13% |
| Shareholder Yield | n/a |
| Earnings Yield | -2.35% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |